BioCina and NovaCina Merge to Strengthen CDMO Market

Deal News | Jan 13, 2025 | PR Newswire Cision BioCina

In a significant development for the global Contract Development and Manufacturing Organization (CDMO) sector, BioCina and NovaCina have announced their strategic merger, aimed at establishing a formidable brand in both biopharmaceutical and small-molecule contract manufacturing. The unified entity, maintaining the BioCina name, will offer an integrated suite of services ranging from cell line and process development to clinical and commercial drug substance manufacturing and sterile drug product filling. This merger leverages BioCina's expertise in process development for microbial, plasmid DNA, and mRNA modalities at its Adelaide, South Australia facility, along with NovaCina's state-of-the-art sterile filling operations in Perth, Western Australia, which has a history of producing over 600 biological and small-molecule products. Mark W. Womack will continue as CEO, leading the company with a proven track record in customer-centric growth. The merger captures the evolving needs of pharmaceutical developers seeking reliable and trusted CDMO partners for efficient regulatory-compliant product market entry. BioCina boasts a strong regulatory compliance record with FDA, EMA, TGA, and Health Canada approvals and benefits from Australia's substantial CDMO tax incentives.

Sectors

  • Biopharmaceuticals
  • Contract Development and Manufacturing Organization (CDMO)

Geography

  • Australia – The merger involves companies operating in Adelaide, South Australia, and Perth, Western Australia, making Australia the primary geographical focus.
  • Global – Given the worldwide impact and market reach of BioCina, the merger has implications across the USA, Europe, Asia, and beyond.

Industry

  • Biopharmaceuticals – This industry is relevant because the article discusses the merger of BioCina and NovaCina, which aims to enhance offerings in the biopharmaceutical manufacturing sector.
  • Contract Development and Manufacturing Organization (CDMO) – A CDMO provides comprehensive services from drug development through manufacturing, a central focus of the merger discussed in the article.

Financials

    Participants

    NameRoleTypeDescription
    BioCinaMerging CompanyCompanyA global CDMO based in Adelaide, known for its expertise in microbial, plasmid DNA, and mRNA process development and manufacturing.
    NovaCinaMerging CompanyCompanyA CDMO with a state-of-the-art sterile filling facility in Perth, joining forces with BioCina.
    Mark W. WomackCEOPersonCEO of BioCina, leading the merger with a background in driving growth in biopharma organizations.
    Masood TayebiExecutive DirectorPersonCo-founder and Executive Director of the Bridgewest Group, the parent company of BioCina and NovaCina.
    Bridgewest GroupParent CompanyCompanyThe parent company of BioCina and NovaCina, overseeing the merger.